MB
MPM BioImpact Portfolio holdings
AUM
$874M
1-Year Est. Return
79.23%
This Fund
S&P 500
1 Year Est. Return
+79.23%
AUM
$874M
AUM Growth
+$263M
(+43%)
Holding
55
Top Buys
| 1 | +$53.3M | |
| 2 | +$45.7M | |
| 3 | +$34.2M | |
| 4 |
Corvus Pharmaceuticals
CRVS
|
+$21.6M |
| 5 |
UroGen Pharma
URGN
|
+$17.5M |
Top Sells
| 1 | +$33.1M | |
| 2 | +$25.3M | |
| 3 | +$17.8M | |
| 4 |
Alkermes
ALKS
|
+$16.5M |
| 5 |
Vera Therapeutics
VERA
|
+$16.4M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
ARS Pharmaceuticals
SPRY
$917M
| – | – |
-1,303,399
|
|
||
|
52
Vera Therapeutics
VERA
$2.9B
| – | – |
-563,075
|
|
||
53
Wave Life Sciences
WVE
$2.59B
| – | – |
-1,505,262
|
|
||
54
Zai Lab
ZLAB
$2.15B
| – | – |
-745,060
|
|
||
|
RAPP
55
Rapport Therapeutics
RAPP
$1.38B
| – | – |
-71,807
|
|